Tioma's broad basket

Tioma Therapeutics Inc. will avoid putting its eggs in one basket and use last week's tranched $86 million series A round to launch a broad clinical program targeting CD47.

President and CEO John Donovan said the round should enable Tioma to generate clinical proof of concept over the next three years for multiple anti-CD47 antibodies across a range of undisclosed tumor types, both as monotherapies and in combination with checkpoint inhibitors...